[Current post-surgical treatment strategies in first-line ovarian cancer].
Stratégies thérapeutiques post-chirurgicales actuelles dans les cancers de l’ovaire en première ligne de traitement.
Bevacizumab
Bévacizumab
Cancer de l’ovaire
Homologous recombination
Inhibiteur de PARP
Ovarian cancer
PARP inhibitor
Recombinaison homologue
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
28 Feb 2023
28 Feb 2023
Historique:
received:
14
10
2022
revised:
18
12
2022
accepted:
29
01
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
aheadofprint
Résumé
Although the management of epithelial ovarian cancer has evolved significantly over the past few years, it remains a public health issue, as most patients are diagnosed at an advanced stage and relapse after first line treatment. Chemotherapy remains the standard adjuvant treatment for International Federation of Gynecology and Obstetrics (FIGO) stage I and II tumors, with some exceptions. For FIGO stage III/IV tumors, carboplatin- and paclitaxel-based chemotherapy are the standard of care, in combination with targeted therapies, especially bevacizumab and/or poly-(ADP-ribose) polymerase inhibitors, that have become a key milestone of first-line treatment. Our decision making for the maintenance therapy is based on the FIGO stage, tumor histology, timing of surgery (i.e. primary or interval debulking surgery), residual tumor, response to chemotherapy, BRCA mutation and homologous recombination (HR) status.
Identifiants
pubmed: 36863923
pii: S0007-4551(23)00089-9
doi: 10.1016/j.bulcan.2023.01.020
pii:
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.